BeyondSpring is trading at $0.85, up 9.92%, in after-hours trading; available evidence does not establish a cause for the rise. - September 29: BeyondSpring announced FDA Fast Track designation for plinabulin plus docetaxel and a transaction involving its China subsidiary to help advance Phase 3 DUBLIN-4. - The regular session closed at $0.77, down 30.96%; broader indices were mixed, with no clear market-wide explanation. - The after-hours move follows a volatile week, including a 44.11% gain on September 28.